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Case report
Immune thrombocytopenic purpura (ITP) in adults often
has an infectious, autoimmune, malignant or idiopathic
etiology. Steroid refractoriness occurs in approximately
9% of patients with ITP (1). A rare inherited cause of
ITP secondary to a mutation encoding the Fas gene is
presented, with ongoing complete hematologic response
12 months after anti-CD20 monoclonal antibody
therapy.
A 36 yr-old man of Israeli descent presented with
recent-onset blood blisters in the mouth and a ﬂorid
petechial leg rash. Automated analysis of the peripheral
blood showed severe isolated thrombocytopenia
(8 · 10
9⁄L), with plentiful megakaryocytes present on
bone marrow examination, consistent with a peripheral
cause for thrombocytopenia. The patient was not on any
medications and tests for immune and infective causes of
thrombocytopenia were negative (HIV, Hepatitis B and
C, EBV, CMV, ANA, ENA, ANCA, rheumatoid factor,
anti-cardiolipin antibody, lupus anticoagulant, dissemi-
nated intravascular coagulation screen). The patient had
a history of severe thrombocytopenia in childhood neces-
sitating splenectomy which resulted in a sustained clinical
remission until the current presentation. Importantly,
there was a family history of autoimmune lymphoprolif-
erative syndrome (ALPS) affecting the patient’s niece.
The patient did not respond promptly to high-dose pred-
nisolone (100 mg daily), intravenous immunoglobulin
and azathioprine (Fig. 1C), and then developed severe
anemia (Hb 64 g⁄L) 18 d after initial presentation.
Immune hemolytic anemia was conﬁrmed by the pres-
ence of spherocytosis on the peripheral blood ﬁlm, posi-
tive direct Coombs’ test (IgG), reduced haptoglobin
(0.1 g⁄L; range 0.3–2), raised lactate dehydrogenase
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(200 · 10
9⁄L; range 50–100). CT imaging of the thorax
and abdomen identiﬁed enlargement of a pelvic lymph
node (Fig. 1A), which was weakly ﬂuorodeoxyglucose
(FDG)-avid on positron emission tomography (PET)
scanning. Due to the presence of refractory thrombocyto-
penia, a diagnostic biopsy was not undertaken. In the
peripheral blood, polyclonal hypergammagloblinemia
(IgG 24 g⁄L; range 9–16) was present, and in addition, a
small population of CD4⁄8 double negative T cells
(Fig. 2A). Four doses of Rituximab (375 mg⁄m
2)g i v e na t
weekly intervals resulted in brisk normalization of the
platelet count (Fig. 1C), a normal reticulocyte count
(85 · 10
9⁄L) 1 month later and complete resolution of the
previous radiological abnormalities on a follow-up CT
scan (Fig. 1B). On review 12 months after initial presenta-
tion, the patient remains in hematological remission. The
patient’s niece, who had a long history of refractory ITP,
was known to have a heterozygous Fas mutation (also
termed TNFRSF6, CD95, Apo-1) affecting the donor
splice site of intron 7 (IVS7+2 T>C; personal communi-
cation Fre ´ de ´ ric Rieux-Laucat). This previously published
frameshift mutation leads to the addition of four intron
bases to the RNA sequence, resulting in a premature stop
codon and truncation of the cytoplasmic death domain of
Fas (2). The mutant Fas protein has dramatically reduced
death receptor function. DNA from the peripheral blood
of the patient conﬁrmed the presence of a heterozygous
IVS7+2 T>C lesion (Fig. 2B).
Programmed cell death, or apoptosis, by activation of
death receptors is a key mechanism for eliminating auto-
reactive lymphocytes. Functional failure of the Fas
(located on chromosome 10q24.1) is associated with
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Figure 1 CT scan of the pelvis at diagnosis
showing an enlarged lymph node (A; white
arrow) which is no longer present (B) one
month after completing Rituximab. (C) Line
graph showing the platelet count ( ), hemoglo-
bin (h) and lymphocyte count (·) over time.
Interventions with prednisolone, azathioprine,
packed red cell transfusion (4RBC), intravenous
immunoglobulin (IVIG) and rituximab are shown.
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Figure 2 (A) Flow cytometric analysis (BD Facscalibur , BD Bios-
ciences, Franklin Lakes, NJ, USA) showing 8.4% of T lymphocytes
were CD4⁄CD8 double negative. (B) Exon 7 of the Fas gene and the
ﬂanking intronic sequence was ampliﬁed by PCR from genomic DNA
(Primers 5¢tggccacttttaagtttcactg and 5¢aaaaggaagtaacaaaaagccaaa).
The 292 bp product was directly sequenced with an ABI3130xl
genetic analyzer using the PCR primers as per the BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA)
protocol. The presence of the heterozygous splice donor site mutation
IVS7+2 T>C (arrow) was conﬁrmed by repeat analysis.
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usually manifesting in infancy with lymphadenopathy,
splenomegaly, autoimmune cytopenias and persistence of
CD4⁄8- ‘double negative’ T cells (3). At least 69 unre-
lated families with Fas mutations have been recorded on
the National Human Genome Research Institute data-
base, with most mutations occurring in exon 9, the intra-
cellular death domain of Fas (4). Rarely, the ALPS
phenotype occurs with defects of Fas ligand (ALPS type
Ib), caspase-8 or caspase-10 (ALPS Type II) (5). The
reduced capacity to eliminate lymphocytes in ALPS is
associated with an increased risk of Hodgkin (relative
risk 51) and non-Hodgkin lymphoma (relative risk 14)
(6). In ALPS patients with widespread lymphadenopathy
and suspected lymphoma, PET scanning has been useful
to guide diagnostic biopsies (7). The most effective treat-
ment in symptomatic ITP is splenectomy, which results
in long-term remission in 66% of patients (8). In ALPS
patients failing splenectomy, limited published experience
suggests a role for Rituximab (9) and mycophenolate
mofetil (10) in such cases.
Although the Fas IVS 7+2 (T ﬁ C) mutation has
been previously described by Kasahara et al. (2), limited
clinical information on these rare disorders is available in
the published literature. In the current case, the rapid
increase in platelets was preceded by marked lymphocyte
depletion induced by Rituximab (Fig. 1C), strikingly
similar to a previous case report (9). However, in contrast
to the previously reported case, our patient has not
relapsed 12 months after Rituximab treatment and has
not required additional therapy to maintain a platelet
response (Fig. 1C). Although the rapid platelet response
following Rituximab appears premature, this is well
described in ITP (11). Intravenous immunoglobulin ther-
apy counters immune thrombocytopenia by blocking
macrophage Fc receptor clearance of opsonised platelets.
In addition, Rituximab also eliminates B cells, making it
an ideal drug for B-cell driven autoimmune diseases. This
latter mechanism was likely to be dominant in our patient
as he had previously failed intravenous immunoglobulin
therapy. Although ALPS is typically associated with
expansion of double negative T cells, Fas defects also pre-
vent elimination of autoreactive germinal center B cells
(12), predisposing the patient to autoimmune disease and
rarely, B-cell non-Hodgkin lymphoma (6).
Although it is possible the weakly FDG avid pelvic
node could harbor lymphoma, a percutaneous or laparo-
scopic biopsy was considered too hazardous in a patient
with refractory thrombocytopenia. Of beneﬁt to this
patient, Rituximab is highly effective against low grade
B-cell non-Hodgkin lymphoma (13), enhancing its utility
in this patient.
In conclusion, this report highlights a rare inherited
cause of immune thrombocytopenia in an adult with a
family history of autoimmune cytopenia(s). Gene
scanning conﬁrmed a Fas mutation in the patient and
his affected niece. Finally, the effective use of anti-CD20
monoclonal antibody therapy to treat the autoimmune
complications of this disorder was remarkable and
prevented a protracted course of immunosuppressive
therapy in a patient lacking a spleen.
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